Tenax Q2 Loss Widens to $17.8M, Cash Runway Extended to Q2 2028
TENX has more than doubled off its 52-week low of $5.78 on elevated volume (1.8× avg).
Summary
Tenax Therapeutics reported a Q2 net loss of $17.8 million, wider than the prior year, driven by higher R&D spending on its Phase 3 LEVEL and LEVEL-2 trials. Operating expenses reached $18.78 million. The company extended its cash runway through Q2 2028, aided by $13.4 million in warrant exercises. Topline data from the Phase 3 LEVEL trial is expected in August 2026, with LEVEL-2 enrollment completion by end of 2027. This follows the Q1 report showing a similar loss trend and the recent supply and regulatory agreements for oral levosimendan. The widening loss underscores the burn rate as the company advances its pipeline, but the extended runway reduces near-term financing risk. The upcoming August data readout is the key binary event.
Updates
· SEC 10-Q — On June 29, 2026, Tenax amended its Orion license to extend the U.S. regulatory approval deadline to December 31, 2035, and entered a supply agreement for oral levosimendan with an initial five-year term and automatic three-year renewals.
At the time of this announcement, TENX was trading at $15.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.5M. The 52-week trading range was $5.78 to $19.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.